News

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

As we look to the next year we can expect to see a few of these challenges settle, while others will continue to make headlines. Here are three things healthcare executives should watch.

In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?

The books healthcare executives recommend to other healthcare executives.

Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.

FDA approved an autoinjector to treat rheumatoid arthritis and other diseases. 

Here are five things managed care executives should know about the proposed plan.

While some pharma makers have lowered drug prices and Express Scripts is pushing more branded manufacturers to lower list prices with its new National Preferred Flex Formulary, some manufacturers are raising drug prices.

Express Scripts’ new National Preferred Flex Formulary, which offers lower list prices on certain branded drugs, is a novel way to encourage pharma makers to lower prices.

Frail patients are a  forgotten patient group-here’s how they were left behind and what can be done about it.

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.

Despite concerns about a new opioid that is reportedly 1,000 times more powerful than morphine, FDA recently approved the new painkiller.

Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.

It’s the hot new skill showing up across the resumes and job postings-but what does if have to do with healthcare?

This comprehensive, pay-for-performance approach drives clinical quality and affordability.

Here is the one surprising thing that improves patients’ ability to effectively manage their own health.

Biosimilar agents can help healthcare organizations offer patients more options for their care. So, what’s stopping payers from immediately adding them to their formularies?

As healthcare organizations move toward value-based models of reimbursement, high drug prices can sometimes get in the way of optimal care. Here are three ways that biosimilars may help.

A new cost analysis study presented at Psych Congress 2018, highlights the substantial economic burden among U.S. veterans with treatment-resistant depression and what can be done about it.

Four things you need to know about the Trump Administration’s proposed regs.

The much-anticipated 2018 midterm elections are over, but the effects on healthcare are lasting. What’s next?

Why the top PBMs are so excited about the promise of a new standardized transaction.

As drug costs continue to increase at an unsustainable rate, some hospitals are finding new solutions.

FDA approves the first new flu drug in 20 years. Here’s what’s different about it.

More affordable, more collaborative, and more personalized care is our cancer care challenge. Here’s how we get there.

As President Trump intensifies his battle with German Chancellor Angela Merkel over trade and NATO policies, he should pause to consider the lessons from another German Chancellor-Otto von Bismarck.

A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.